Clinical trials: Skin Diseases, Papulosquamous
Psoriasis
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
This is a 73-day phase II, open label trial of the true human monoclonal antibody RA-18C3 in subjects with moderate to severe plaque psoriasis. Ten (10) subjects will receive 200 mg of RA-18C3 via subcutaneous injection.
- Trial name
- NCT01384630
- Testing
- RA-18C3
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Fluphenazine Decanoate for Psoriasis
We are doing this research study to evaluate the effectiveness and safety of fluphenazine decanoate when injected with a needle into psoriasis lesions in adults. Fluphenazine decanoate is FDA (U.S.
- Trial name
- NCT00356200
- Testing
- Fluphenazine Decanoate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Tufts Medical Center
Pharmacokinetics of ASP015K, Bioavailability of ASP015K
A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation
The purpose of this study is to determine the bioavailability and pharmacokinetics between two different formulations of ASP015K tablets and determine the food effect on the absorption of the new formulation.
- Conditions
- Pharmacokinetics of ASP015K, Bioavailability of ASP015K, Healthy Subjects
- Trial name
- NCT01484964
- Testing
- ASP015K
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis
This is a 52 week Phase 2b study designed to evaluate the efficacy at 16 weeks and to evaluate the safety and efficacy up to 1 year in subjects with active psoriatic arthritis.
- Trial name
- NCT03963401
- Testing
- PF-06700841
- Where
- 48 sites in Australia, Bulgaria and 9 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Oral Squamous Cell Carcinoma, Oral Potentially Malignant Disorder
SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography
This clinical trial aims to assess the efficacy of Optical Coherence Tomography (OCT) in the early diagnosis of oral cancer. It focuses on Oral Potentially Malignant Disorders (OPMDs) as precursors to Oral Squamous Cell Carcinoma…
- Conditions
- Oral Squamous Cell Carcinoma, Oral Potentially Malignant Disorder, Oral Leukoplakia, Proliferative Verrucous Leukoplakia
- Trial name
- SYMILIS OCT (NCT06321003)
- Testing
- OCT (Optical Coherence Tomography)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Palermo
Oral Lichen Planus
Impact of Fluocinonide 0,05% in Oral Lichen Planus
A double-blind placebo-controlled trial is conducted in order to evaluate the efficacy of Fluocinonide 0,05% and determinate the statistical significance of the outcome variables.
- Trial name
- NCT06135805
- Testing
- Fluocinonide 0,05% oral gel
- Where
- Italy
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Catania
Type 2 Diabetes, Psoriasis
Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients
The aim of the study is to evaluate after 4 to 6 months the effects of a GLP-1 analog treatment on psoriatic skin lesions in patients with type 2 diabetes.
- Trial name
- NCT01687582
- Testing
- GLP-1 analog
- Where
- Belgium
- Volunteers
- 10 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Oral Lichen Planus
Intra-oral Treatment of OLP With Rivelin®-CLO Patches
Participants with symptomatic Oral Lichen Planus lesions will be treated with Rivelin® patches containing either 0, 1, 5, or 20 μg clobetasol per patch. Each participant will apply up to 6 patches twice daily for 4 weeks.
- Trial name
- NCT03592342
- Testing
- Clobetasol Propionate
- Where
- 27 sites in United States, Canada and 4 more
- Volunteers
- 140 people
- Sponsor
- Dermtreat
Psoriasis, Psoriatic Arthritis
Recirculating Memory T Cells in the Pathogenesis of Psoriatic Arthritis and Cutaneous Psoriasis
The aim of the study is to investigate the link between pro-inflammatory T cells responses arising in the skin in patients with cutaneous psoriasis and those present in the joints of patients developing psoriatic arthritis.
- Trial name
- NCT03374527
- Testing
- blood sample collection, Synovial Fluid collection
- Where
- Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Psoriatic Arthritis
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
The purpose of this study is to evaluate the efficacy, safety and tolerability of guselkumab in participants with Active Psoriatic Arthritis (PsA).
- Trial name
- NCT02319759
- Testing
- Guselkumab, Ustekinumab
- Where
- 41 sites in United States, Canada and 5 more
- Volunteers
- 149 people
- Sponsor
- Janssen Research & Development, LLC
Alopecia Areata, Vitiligo
A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo
The objective of the study is to explore various clinical and biochemical parameters and their potential associations with disease severity, activity, and prognosis in atopic dermatitis, psoriasis, alopecia areata, and vitiligo.
- Conditions
- Alopecia Areata, Vitiligo, Atopic Dermatitis, Psoriasis
- Trial name
- Derma-001 (NCT06319781)
- Testing
- Observational
- Where
- 3 sites in Denmark
- Volunteers
- 370 people
- Sponsor
- Blueskin AS
Atopic Dermatitis, Psoriasis
A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers
This study is to evaluate the safety, tolerability, and pharmacokinetics of YR001 topical ointment in healthy adult subjects.
- Trial name
- NCT05718921
- Testing
- YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Autoimmune Diseases, Inflammatory Bowel Diseases
Chronic Inflammatory Disease, Lifestyle and Treatment Response
Chronic inflammatory diseases (CID) - including inflammatory bowel diseases (Crohn's disease and ulcerative colitis), rheumatic conditions (rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis), inflammatory skin…
- Conditions
- Autoimmune Diseases, Inflammatory Bowel Diseases, Crohn Disease (CD), Colitis, Ulcerative (UC)
- Trial name
- BELIEVE (NCT03173144)
- Testing
- Primary exposure variable, Other (exploratory) exposure variables
- Where
- 3 sites in Denmark
- Volunteers
- 233 people
- Sponsor
- University of Southern Denmark
Psoriasis
A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan
The purpose of this study is to determine the safety and effectiveness of deucravacitinib for the treatment of plaque psoriasis (PsO) in Japan participants.
- Trial name
- NCT05633264
- Where
- Japan
- Volunteers
- 369 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis, Plaque Type Psorisis
Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis
The goal of this clinical trial is to learn if IRX4204 works to treat plaque psoriasis in adults. It will also learn about the safety of IRX4204.
- Conditions
- Psoriasis, Plaque Type Psorisis, Plaque Psoriasis
- Trial name
- NCT06723171
- Testing
- IRX4204
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Io Therapeutics
Psoriasis
Effectiveness of Artificial Balneotherapy, Phototherapy and Artificial Balneophototherapy in the Treatment of Psoriasis
The purpose of this study is to compare the effectiveness of artificial balneotherapy (AB), phototherapy (PT) and artificial balneophototherapy (BPT) in the treatment of plaque psoriasis, evaluating the plaque area, alteration of…
- Trial name
- NCT02713711
- Testing
- phototherapy, balneotherapy, balneophototherapy
- Volunteers
- 14 people
- Sponsor
- Universidad Católica del Maule
Psoriasis, Psoriatic Arthritis
Psoriasis-Arthritis & Bone Program
Purpose and rationale: To define the role of IL-17 as a mediator of structural bone lesions in psoriasis patients and patients with PsA. Primary Objective is the improvement of the PsAMRIS synovitis score baseline vs. week 24.
- Trial name
- PSARTROS (NCT02483234)
- Testing
- secukinumab
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Psoriasis
The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis
The purpose of this study is to evaluate the efficacy of adding methotrexate to etanercept compared with etanercept monotherapy as measured by the percentage of participants achieving a 75% improvement from baseline in the…
- Trial name
- NCT01001208
- Testing
- Methotrexate, Etanercept
- Volunteers
- 478 people
- Sponsor
- Amgen
Ankylosing Spondylitis, Psoriatic Arthritis
Functional Limitations Due To The Foot Involvement In Spondyloarthritis
Seronegative spondyloarthritis (SpA) is a group of rheumatic diseases Foot involvement of the SpA is common and enthesitis, erosive changes or ankylosis are the frequent lesions.
- Trial name
- NCT01833468
- Volunteers
- 30 people
- Sponsor
- Vakif Gureba Training and Research Hospital
Psoriatic Arthritis
An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients
Given the role of IL-17 in the development of entheseal-driven pathology, a therapeutic strategy aimed at blocking IL-17 would be a logical option for the treatment of enthesitis in psoriatic arthritis patients.
- Trial name
- NCT04967950
- Testing
- Secukinumab 300 MG, Secukinumab 150 MG, Methotrexate
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.